Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites

Inclusion Criteria: * Patients will be included in the case of: * Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2 * Participants must be 18 years of age or older * Have ascites of malignant disease * Have symptoms related to ascites * Ascites Index above 0.05 (AI ˃ 0.05) * Be an English speaking patient or have an interpreter available * Be able to understand and comply with all study requirements and the implications of off-label use of intraperitoneal Bevacizumab * Have had at least two paracentesis within the last 4 weeks Exclusion Criteria: * Patients will be excluded in the case of: * Ascites due to non-malignant cause * Concurrent treatment with systemic chemotherapy that has a realistic chance of controlling the ascites * Concurrent treatment with intraperitoneal Bevacizumab * life expectancy of less than 2 weeks * A history of bowel perforation or fistula * Symptoms or signs suggestive of bacterial peritonitis * Child's C cirrhosis * Uncontrolled hypertension * Surgery within 28 days of catheter treatment * Evidence of coagulopathy * Symptoms suggestive of bowel obstruction * Major surgery, open biopsy or significant traumatic injury within seven (7) days of first study drug--including neurosurgery. * Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements. * Concurrent severe illness such as active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements * Patients who are pregnant or lactating (females of childbearing potential must have a negative pregnancy test prior to participation) * Patients with pre-existing 3 + or greater urine dipstick reading proteinuria